Application | Comment | Organism |
---|---|---|
medicine | high-dose mini-TyrRS (600 microgram/kg/day) augments while low-dose mini-TyrRS (3 microgram/kg/day), inhibits angiogenesis in the ischemic mouse ear. Enhanced angiogenesis is associated with increased CD45- and CD4-positive leukocyte accumulation. Mini-TyrRS also has biphasic actions on both basal and mustard oil-evoked and VEGF-evoked leakage of Evan's blue dye-albumin in nonischemic ear and in endothelial cell monolayers, that is, low-dose inhibited and high-dose augmented leakage. Mini-TyrRS has dose-dependent biphasic effects on ischemic angiogenesis and vascular permeability in vivo, that is, antiangiogenic and antipermeability activities at low concentration and proangiogenic, propermeability activities at high concentrations | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
additional information | mutation of the ELR-motif to EYR abolishes the effect on ischemic angiogenesis, leukocyte recruitment, and vascular permeability | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
endothelial cell | - |
Mus musculus | - |
muscle | mini-TyrRS is reduced in extracts of ischemic calf muscle and in thoracic aorta explants exposed to hypoxia or VEGF | Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
mini-tyrosyl-tRNA synthetase | N-terminal domain of tyrosyl-tRNA synthetase | Mus musculus |
mini-TyrRS | - |
Mus musculus |